Adverum Biotechnologies Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Adverum Biotechnologies Inc (ADVM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Adverum Biotechnologies Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 2M vs 57,195M combined for its competitors (0.0% combined share).
- Peer differentiation: Revenue per employee of $0.01M compares with $2.18M for the peer group (0.0x).
- Structure: Adverum Biotechnologies Inc operates in the following segments: Reportable.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Adverum Biotechnologies Inc vs. its Competitors, Q3 2025
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Adverum Biotechnologies Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Adverum Biotechnologies Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Adverum Biotechnologies Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (91) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Adverum Biotechnologies Inc's competitor groups requires a Commercial License.
Adverum Biotechnologies Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Adverum Biotechnologies Inc | - | - | - | Yes |
| Competitors combined (25) | ||||
| High-Confidence Competitors (107) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ADVM Stock Performance relative to its Competitors
ADVM Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Alector Inc | 282.9% | Outperformed |
| 2 | Liquidia Corporation | 282.9% | Outperformed |
| 3 | Exelixis Inc | 282.9% | Outperformed |
| 4 | Halozyme Therapeutics Inc | 282.9% | Outperformed |
| 5 | Biogen Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Adverum Biotechnologies Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Adverum Biotechnologies Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Adverum Biotechnologies Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Adverum Biotechnologies Inc |
102.40 | 1.60 |
 Amgen Inc |
250,468.48 | 38,095.00 |
 Biogen Inc |
36,706.13 | 10,297.30 |
 Exelixis Inc |
17,792.81 | 2,496.86 |
 Halozyme Therapeutics Inc |
12,561.51 | 1,663.74 |
 Mirum Pharmaceuticals Inc |
6,190.19 | 670.78 |
| SUBTOTAL | 342,401.75 | 57,300.32 |
Sign in to see all competitors of Adverum Biotechnologies Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Adverum Biotechnologies Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Adverum Biotechnologies Inc's Competitors Named by the Company
Competitive relationships identified from Adverum Biotechnologies Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Passage Bio Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Petvivo Holdings Inc | Company report | 85% |
| Regencell Bioscience Holdings Limited | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Mangoceuticals Inc | Company report | 85% |
| Fibrobiologics Inc | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Acumen Pharmaceuticals Inc | Company report | 85% |
| Crispr Therapeutics Ag | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Halozyme Therapeutics Inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Denali Therapeutics Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Neurosense Therapeutics Ltd | Company report | 85% |
| Roche Holding AG | Company report | 85% |
| Intellia Therapeutics Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Shuttle Pharmaceuticals Holdings Inc | Company report | 85% |
| Bristol-Myers Squibb | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Redwoods Acquisition Corp | Company report | 85% |
| Contineum Therapeutics Inc | Company report | 85% |
| Definium Therapeutics Inc | Company report | 85% |
| Nyxoah Sa | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Abivax Sa | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Coya Therapeutics Inc | Company report | 85% |
| MNMD | Company report | 85% |
| Cytosorbents Corporation | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Innate Pharma Sa | Company report | 85% |
| Bicara Therapeutics Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Reshape Lifesciences Inc | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Novo Nordisk A | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Maia Biotechnology Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Bicycle Therapeutics Plc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Outlook Therapeutics | Company report | 85% |
| Generation Bio Co | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Ocular Therapeutix | Company report | 85% |
| REGENXBIO | Company report | 85% |
| Jupiter Neurosciences Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Kodiak Sciences | Company report | 85% |
| Journey Medical Corp | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Opthea | Company report | 85% |
| Prime Medicine Inc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Qsam Biosciences Inc | Company report | 85% |
| Lumos Pharma Inc | Company report | 85% |
| Peak Bio Inc | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Point Pharmaceuticals | Company report | 85% |
| Mannkind Corporation | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Molecular Partners Ag | Company report | 85% |
| OCUP | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Xeris Biopharma Holdings Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Abvc Biopharma Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Opus Genetics Inc | Company report | 85% |
| 4D Molecular Therapeutics | Company report | 85% |
| Better Therapeutics Inc | Company report | 85% |
| Hoffmann-La Roche Ltd. | Company report | 85% |
| UCB | Company report | 85% |
| Bayer | Company report | 85% |
| Sab Biotherapeutics Inc | Company report | 85% |
| Scholar Rock | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Graybug Vision | Company report | 85% |
| Janssen | Company report | 85% |
| Inflarx N V | Company report | 85% |
| Fresh Tracks Therapeutics Inc | Company report | 85% |
| Alector Inc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Viracta Therapeutics Inc | Company report | 85% |
| Harmony Biosciences Holdings inc | Company report | 85% |
| Acceleron Pharma inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Generic Pharmaceuticals | Company report | 85% |
| Sanofi | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Electrocore Inc | Company report | 85% |
| Vistagen Therapeutics Inc | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Edesa Biotech Inc | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Sangamo Therapeutics Inc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Bolt Biotherapeutics Inc | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Kiniksa Pharmaceuticals International Plc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Ultragenyx Pharmaceutical Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Sage Therapeutics Inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Argenx Se | Company report | 85% |
| Organon and Co | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
| Wave Life Sciences Ltd | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Biohaven Ltd | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Precigen Inc | Company report | 85% |
| Precision Biosciences Inc | Company report | 85% |
| Affimed N v | Company report | 85% |
Company report basis, confidence, active dates and source counts for Adverum Biotechnologies Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Adverum Biotechnologies Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Adverum Biotechnologies Inc | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Liquidia Corporation | Single reportable segment 100.00 % |
| Sarepta Therapeutics Inc | All Other Segments 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Adverum Biotechnologies Inc .
Adverum Biotechnologies Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Adverum Biotechnologies Inc | 102 | 13,248 | -1,689,190 |
| Amgen Inc | 250,468 | 2,930,385 | 672,538 |
| Biogen Inc | 36,706 | 1,372,973 | 46,333 |
| Exelixis Inc | 17,793 | 2,176,862 | 1,454,397 |
| Halozyme Therapeutics Inc | 12,562 | 3,933,187 | 977,768 |
| Mirum Pharmaceuticals Inc | 6,190 | 1,803,167 | -2,429,780 |
| PEERS TOTAL | 342,299 | 2,181,728 | 377,225 |
Sign in to see all peers for Adverum Biotechnologies Inc .
Adverum Biotechnologies Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Exelixis Inc | United States 92.47 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Adverum Biotechnologies Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 158 companies in Adverum Biotechnologies Inc's industry classification, broader than the peer set above. Market cap in millions of $.Adverum Biotechnologies Inc ranks #0 of 158 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,353, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 250,468 | 26.02 % |
| 2 | Gilead Sciences Inc | 207,444 | 21.55 % |
| 3 | Moderna Inc | 101,168 | 10.51 % |
| 4 | Argenx Se | 61,223 | 6.36 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Mesoblast Limited | 1,234 | 5.2% |
| 9 | Exelixis Inc | 1,234 | 5.2% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 0 | Adverum Biotechnologies Inc | 102 | 0.00 % |
Market cap and industry share for the rest of Adverum Biotechnologies Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-12-08.
Adverum Biotechnologies Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (160 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 27.3x | - |
| EV / EBITDA | - | 17.0x | - |
| P/B | 13.0x | 5.1x | +7.9x |
| Return on Equity | -3,844.85 % | industry aggregate | -3,857.04 % |
| Return on Invested Capital | -130.77 % | -11.80 % (avg) | -118.97 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Adverum Biotechnologies Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2016 | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -88.57 % | 500.00 % | -11.20 % | - | - | - | - | - |
| Operating Margin | -5,852.08 % | -3,182.64 % | -5,079.96 % | - | - | - | - | - |
| Return on Invested Capital | -3.24 % | -15.20 % | -18.56 % | -18.20 % | -17.78 % | -28.54 % | -46.37 % | -51.37 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Adverum Biotechnologies Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,353 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Adverum Biotechnologies Inc's dedicated Suppliers and Customers pages, not here.
Adverum Biotechnologies Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 3,857.0 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (62.50 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-3.1% annualized).
Methodology: see Methodology: SWOT Analysis.
Adverum Biotechnologies Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Adverum Biotechnologies Inc | 1.44 | 2.40 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Biogen Inc | 0.08 | 2.33 | 0.38 |
| Exelixis Inc | 0.84 | 3.37 | - |
| Halozyme Therapeutics Inc | 0.60 | 2.38 | 8.67 |
| Mirum Pharmaceuticals Inc | 1.21 | 2.38 | 4.27 |
Sign in to see all peers for Adverum Biotechnologies Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Adverum Biotechnologies Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Adverum Biotechnologies Inc | Q3 2025 | - | - |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Biogen Inc | Q3 2026 | +10.6 % | - |
| Exelixis Inc | Q3 2026 | +10.2 % | -51.1 % |
| Halozyme Therapeutics Inc | Q2 2026 | +47.7 % | +39.2 % |
| Mirum Pharmaceuticals Inc | Q3 2026 | +39.6 % | - |
| PEERS TOTAL | +13.4 % | +11.2 % |
Sign in to see all peers for Adverum Biotechnologies Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Adverum Biotechnologies Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Adverum Biotechnologies Inc | Q3 2025 | - | -35.7 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Biogen Inc | Q3 2026 | +11.0 % | -21.6 % |
| Exelixis Inc | Q3 2026 | +41.2 % | +67.9 % |
| Halozyme Therapeutics Inc | Q2 2026 | +70.8 % | +167.0 % |
| Mirum Pharmaceuticals Inc | Q3 2026 | - | +597.9 % |
Sign in to see all peers for Adverum Biotechnologies Inc .
Adverum Biotechnologies Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Adverum Biotechnologies Inc | - | - | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Biogen Inc | 1.13% | 1.26% | 1.86% |
| Exelixis Inc | 63.88% | 75.01% | 85.83% |
| Halozyme Therapeutics Inc | 16.55% | 19.99% | 180.63% |
| Mirum Pharmaceuticals Inc | - | - | - |
Sign in to see all peers for Adverum Biotechnologies Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Adverum Biotechnologies Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Adverum Biotechnologies Inc | - | 63.88 |
| Amgen Inc | 28.60 | 6.57 |
| Biogen Inc | 106.05 | 3.56 |
| Exelixis Inc | 28.63 | 7.13 |
| Halozyme Therapeutics Inc | 30.39 | 7.55 |
| Mirum Pharmaceuticals Inc | - | 9.23 |
| PEERS AVERAGE | 35.29 | 5.98 |
Sign in to see all peers for Adverum Biotechnologies Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.